MARKET

ATHX

ATHX

Athersys
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.420
-0.050
-3.40%
Opening 10:03 09/20 EDT
OPEN
1.420
PREV CLOSE
1.470
HIGH
1.430
LOW
1.410
VOLUME
270.42K
TURNOVER
--
52 WEEK HIGH
3.030
52 WEEK LOW
1.350
MARKET CAP
321.28M
P/E (TTM)
-3.1216
1D
5D
1M
3M
1Y
5Y
Do Options Traders Know Something About Athersys (ATHX) Stock We Don't?
Zacks.com · 08/16 13:33
How Aging-Related Conditions Are Increasing The Treatment Burden For Older Patients
/PRNewswire/ -- - The normal aging process is characterized by a progression of physiologic events that occur throughout the life cycle. Changes associated with aging occur throughout the body and are most prominent in the later years. Changes in the musc...
PR Newswire - PRF · 08/13 12:30
Athersys Partner HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment for Ischemic Stroke
CLEVELAND, August 10, 2021--Athersys partner HEALIOS K.K. announces full enrollment of the TREASURE clinical study evaluating MultiStem® cell therapy for stroke patients.
Business Wire · 08/10 13:17
Athersys Partner Completes Enrollment in Phase 2/3 Trial of MultiStem Cell Therapy for Ischemic Stroke; Shares Rise Midday
MT Newswires · 08/10 12:32
Athersys: Q2 Earnings Insights
Shares of Athersys (NASDAQ:ATHX) increased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were unchanged 0.00% over the past year to ($0.10), which were in line with the estimate of ($0.10).
Benzinga · 08/09 21:11
Athersys Q2 EPS $(0.10), Inline
Athersys (NASDAQ:ATHX) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
Benzinga · 08/09 21:07
BRIEF-Athersys Posts Quarterly Loss Per Share Of $0.10
reuters.com · 08/09 20:51
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the...
Benzinga · 08/08 14:03
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATHX. Analyze the recent business situations of Athersys through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATHX stock price target is 5.75 with a high estimate of 7.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 195
Institutional Holdings: 56.43M
% Owned: 24.94%
Shares Outstanding: 226.26M
TypeInstitutionsShares
Increased
38
1.82M
New
27
2.40M
Decreased
31
11.50M
Sold Out
26
2.00M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.17%
Pharmaceuticals & Medical Research
-0.61%
Key Executives
Non-Executive Chairman/Independent Director
Ismail Kola
President/Chief Executive Officer/Chief Operating Officer
William Lehmann
Chief Financial Officer
Ivor Macleod
Executive Vice President/Chief Scientific Officer/Director
John Harrington
Director
Hardy Kagimoto
Director
Kenneth Traub
Independent Director
Katherine Kalin
Independent Director
Lorin Randall
Independent Director
Baiju Shah
Independent Director
Jane Wasman
Independent Director
Jack Wyszomierski
No Data
About ATHX
Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Webull offers kinds of Athersys Inc stock information, including NASDAQ:ATHX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATHX stock methods without spending real money on the virtual paper trading platform.